MSH Pharma
MSH Pharma, officially known as MSH Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in Turkey (TR). Founded in 2001, the company has established a strong presence in various operational regions, focusing on the development and distribution of high-quality pharmaceutical products. Specialising in therapeutic areas such as oncology, cardiology, and infectious diseases, MSH Pharma is recognised for its innovative approach to drug formulation and delivery. The company’s core offerings include a diverse range of generic and branded medications, distinguished by their efficacy and safety profiles. With a commitment to research and development, MSH Pharma has achieved significant milestones, positioning itself as a trusted name in the market. Its dedication to quality and patient care has garnered notable achievements, solidifying its reputation as a leader in the pharmaceutical sector.
DitchCarbon Score
How does MSH Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MSH Pharma's score of 3 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
MSH Pharma's reported carbon emissions
MSH Pharma, headquartered in Turkey (TR), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of concrete emissions data, it is essential to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for reducing greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As MSH Pharma continues to navigate its sustainability journey, it may consider establishing measurable targets and reporting frameworks to align with industry standards and contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MSH Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
